Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

Follistatin 344

Buy Follistatin 344 France Peptide

Follistatin 344 (FS344) is a naturally occurring protein that functions as an antagonist of myostatin and activin, two members of the transforming growth factor-beta (TGF-β) superfamily. Studies have shown these proteins play a crucial role in the regulation of skeletal muscle mass, where myostatin inhibits muscle growth and differentiation, while activin stimulates the release of follicle-stimulating hormone (FSH) by pituitary cells.

FS344 has garnered significant attention in research due to its potential applications in muscle hypertrophy and atrophy treatment. By binding to and neutralizing myostatin and activin, France research suggests FS344 can stimulate muscle growth and prevent muscle wasting, making it a promising therapeutic agent for conditions such as muscular dystrophy, sarcopenia, and cachexia.

Showing all 3 results

Potential Benefits of Follistatin 344 Peptide

  • Orthopedic Applications: Research suggests Follistatin has shown potential in inhibiting myostatin, a protein that inhibits muscle growth. This property could have significant implications in orthopedics, potentially helping with muscle regeneration and growth [1].
  • Treatment of Muscular Dystrophy: Studies have demonstrated that follistatin can potentially increase therapeutic benefits in muscular dystrophy. In one study, an antibody against the HA tag present on the follistatin-344 gene was used as a probe [2]. Another study showed that micro-dystrophin and follistatin co-delivery restored muscle function in an aged DMD model [3].
  • Muscle Regeneration: Studies on an engineered follistatin therapeutic showed promise for improving muscle regeneration [4].
  • Increasing Lean Muscle Mass: A study involving mice demonstrated that nanoparticle-mediated hepatic delivery of follistatin mRNA resulted in increased lean muscle mass [5].
  • Localized hypertrophy of skeletal muscle: Research findings indicate that ACE-083, a follistatin-based ligand trap, has demonstrated functional improvement in neuromuscular disease models through the induction of localized hypertrophy of skeletal muscle [6].
  • Becker Muscular Dystrophy Trial: In research, a phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy showed potential benefits [7].

References

[1] https://pubmed.ncbi.nlm.nih.gov/19208403/

[2] https://pubmed.ncbi.nlm.nih.gov/31890729/

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3895965/

[4] https://pubmed.ncbi.nlm.nih.gov/24627466/

[5] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6276093/

[6] https://pubmed.ncbi.nlm.nih.gov/31388039/

[7] https://pubmed.ncbi.nlm.nih.gov/25322757/

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://france.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.